I am not worried about finance because I think that Caldwell and team are on the cusp of obtaining larger investment monies and much greater things for their bond holders and the common shareholders. They have sufficient finance to cover the program for the next two years. Cha, a multimillion dollar company and investor in ACTC will not jeopardize their investment and their own bio plans.
The two guys at the top of ACTC are not dummies. Far from it.
Mr. Caldwell brings over 30 years of management expertise to Advanced Cell Technology and has worked with emerging technology companies, public companies and corporate restructurings. During his career he has served in senior executive positions both in marketing and finance. He has broad industry experience, which includes advising corporations, both public and private, in technology, pharmaceuticals, telecommunications, retailing, real estate, hospitality, publishing, and transportation. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton School of Finance.
Dr Lanza has written many books on the subject and worked along side the great Christian Barnard. The person who performed the first heart transplant in the world. ACTC is following a logical path through OTC status, submission to FDA and NIH and preparation of stage 1 trials. They would not have continued that process had they any doubts that their program was to be denied by the FDA.
We shall see a go ahead anytime from now until the end of March. I don't won't to be without a substantial holding when the news hits the airwaves.
News 
Market Data 
Discover 
AI
